SynOx Therapeutics

SynOx Therapeutics is focused on developing emactuzumab for the treatment of TGCT and other indications, backed by a strong investor syndicate.

[SynOx Therapeutics @SynOx_Tx]

Knowledge helps patients and carers make confident choices. That's why we're proud to sponsor TGCT Support Day of Learning 2026. 💙 This event brings together people living with TGCT. Taylor and Sigrid from our team will be there to say hello. #TGCT #TDOL2026 #PatientSupport

[SynOx Therapeutics @SynOx_Tx]

We're thrilled to welcome Taylor Salinardi as VP of Global Medical Affairs at SynOx Therapeutics 🌱
Taylor joins SynOx Therapeutics at an exciting time and will play an important role in the company’s next stage of growth. 🌿💡 #MedicalAffairs #SynOxTherapeutics

[SynOx Therapeutics @SynOx_Tx]

SynOx reports positive Phase 3 TANGENT topline results for emactuzumab in TGCT — a major step forward for patients. Years of work from an exceptional team and committed investors have brought us here. This is a wonderful milestone. #TGCT #PVNS #biotech #patientsfirst

[SynOx Therapeutics @SynOx_Tx]

Today on Rare Disease Day, we stand with everyone affected by rare diseases, including those living with TGCT.

Your strength inspires our work to listen, advance science, and develop treatments that make a real impact. Every patient deserves hope.

#RareDiseaseDay #PatientsFirst

[SynOx Therapeutics @SynOx_Tx]

Today, we announced the appointments of Charles “Chip” R. Romp and Tom J. Heyman to our Board of Directors. These strategic additions strengthen our alignment with our forward-looking vision as we advance emactuzumab toward key regulatory and commercial milestones.

[SynOx Therapeutics @SynOx_Tx]

Excited to welcome Philip Astley-Sparke to SynOx Therapeutics. This transition is a signal of where we’re going as a company. With our Phase 3 program well underway, a strengthened U.S. presence, and growing momentum, we’re entering a time of real possibility. #TGCT #PVNS

[SynOx Therapeutics @SynOx_Tx]

Rare Disease Month @Liferaftgroup #TGCT @SynOx_Tx

[SynOx Therapeutics @SynOx_Tx]

Rare Disease Month with SPAGN

[SynOx Therapeutics @SynOx_Tx]

Proud to present at CTOS 2024 on the Phase 3 clinical trial of emactuzumab, a potentially best-in-class CSF-1R mAb for the treatment of patients with TGCT. The study is named TANGENT. Details can be found on https://t.co/xANb8BmnqY (ID: NCT05417789). #tgct #pvns @TGCTSupportort

[SynOx Therapeutics @SynOx_Tx]

July is Sarcoma Awareness Month. Tenosynovial giant cell tumor (TGCT) is a debilitating disease that also invades soft tissues and causes joint damage, swelling, pain, and reduced function. At SynOx we are dedicated to supporting this vision.
#SarcomaAwareness #TGCT #synox

[SynOx Therapeutics @SynOx_Tx]

https://t.co/4VjfkGhHa2

[SynOx Therapeutics @SynOx_Tx]

Today, SynOx Therapeutics announces it has secured up to $35m debt financing with Hercules Capital.

This follows our recent $75m Series B financing and will provide SynOx with the flexibility to fund additional work in #TGCT while also exploring other potential indications.

[Business Post @businessposthq]

SynOx Therapeutics has raised $75 million (€70.4 million) in funding to continue the development of Emactuzumab, an antibody that targets tumours https://t.co/DRWkJAylX6

[SynOx Therapeutics @SynOx_Tx]

https://t.co/FDuFzPqB1H

[SynOx Therapeutics @SynOx_Tx]

Excited to announce close of our $75 million Series B financing, which was co-led by @Forbion and @HealthCap, as well as our new investor @Bioqube Ventures, who we are delighted to welcome. Please see the full press release link in the comments below #biotech #financing #tgct

[SynOx Therapeutics @SynOx_Tx]

https://t.co/FDuFzPqB1H

[SynOx Therapeutics @SynOx_Tx]

Excited to announce close of our $75 million Series B financing, which was co-led by @Forbion and @HealthCap, as well as our new investor @Bioqube Ventures, who we are delighted to welcome. Please see the full press release link in the comments below #biotech #financing #tgct

[SynOx Therapeutics @SynOx_Tx]

SynOx Supports Rare Disease Day
#rarediseasday #tgct #pvns #emactuzumab

[SynOx Therapeutics @SynOx_Tx]

SynOx’s lead candidate #Emactuzumab designated an #OrphanMedicinalProduct for the treatment of Tenosynovial Giant Cell Tumour (#TGCT). Read the full press release here: https://t.co/Z5IfSinKRC and more about TANGENT (#TANGENT) here: https://t.co/v71tyW9Vi6